aap Implantate AG Cash Flow Conversion Efficiency

Latest as of June 2022: -0.052x

aap Implantate AG cash flow conversion efficiency. Based on the latest financial reports, aap Implantate AG (AAQ1) has a cash flow conversion efficiency ratio of -0.052x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-659.50K ≈ $-771.02K USD) by net assets (€12.63 Million ≈ $14.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of aap Implantate AG (2016–2024)

Cash flow conversion efficiency of aap Implantate AG from 2016 to 2024. This chart illustrates how aap Implantate AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View aap Implantate AG share price for real-time trading data and today's change.

aap Implantate AG Cash Flow Conversion Ratio Explained

aap Implantate AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

aap Implantate AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of aap Implantate AG ranked by their cash flow conversion efficiency. Also see market cap of aap Implantate AG for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Kainos Medicine Inc KQ:284620	-0.400x
Broadpeak SA PA:ALBPK	0.386x
Maniker KO:027740	0.060x
Grafton Group plc LSE:GFTU	0.080x
ALPHA EXPLORATION LTD F:J0C	-0.010x
N.D. Rubber Public Company Limited BK:NDR	0.014x
Canfor Pulp Products Inc. TO:CFX	-0.064x
K-Tech Solutions Company Limited Class A Ordinary Shares NASDAQ:KMRK	N/A

Annual Cash Flow Conversion Efficiency for aap Implantate AG (2016–2024)

The table below shows the annual cash flow conversion efficiency of aap Implantate AG from 2016 to 2024. Review AAQ1 FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€10.46 Million ≈ $12.23 Million	€-1.12 Million ≈ $-1.31 Million	-0.107x	+70.14%
2023-12-31	€8.10 Million ≈ $9.47 Million	€-2.92 Million ≈ $-3.41 Million	-0.360x	-143.82%
2022-12-31	€12.83 Million ≈ $15.00 Million	€-1.89 Million ≈ $-2.21 Million	-0.148x	+23.67%
2021-12-31	€12.78 Million ≈ $14.94 Million	€-2.47 Million ≈ $-2.89 Million	-0.193x	+45.86%
2020-12-31	€10.29 Million ≈ $12.03 Million	€-3.67 Million ≈ $-4.30 Million	-0.357x	-16.83%
2019-12-31	€18.87 Million ≈ $22.06 Million	€-5.77 Million ≈ $-6.74 Million	-0.306x	-80.31%
2018-12-31	€34.92 Million ≈ $40.82 Million	€-5.92 Million ≈ $-6.92 Million	-0.170x	-32.90%
2017-12-31	€42.56 Million ≈ $49.76 Million	€-5.43 Million ≈ $-6.35 Million	-0.128x	+3.01%
2016-12-31	€54.78 Million ≈ $64.04 Million	€-7.20 Million ≈ $-8.42 Million	-0.131x	--

About aap Implantate AG

F:AAQ1 Germany Medical Devices

Market Cap

$24.09 Million

€20.60 Million EUR

Market Cap Rank

#24361 Global

#2104 in Germany

Share Price

€1.40

Change (1 day)

-1.41%

52-Week Range

€1.27 - €2.22

All Time High

€21.70